EAM-2201

From Wikipedia, the free encyclopedia
Jump to: navigation, search
EAM-2201
EAM-2201 structure.png
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C26H26FNO
Molar mass 387.488 g/mol
3D model (JSmol)

EAM-2201 (4'-ethyl-AM-2201, 5"-fluoro-JWH-210) is a drug that presumably acts as a potent agonist for the cannabinoid receptors.[1] It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in July 2012 as an ingredient in synthetic cannabis smoking blends[2] Like the closely related MAM-2201 which had been first reported around a year earlier, EAM-2201 thus appears to be another novel compound invented by designer drug suppliers specifically for recreational use. Structurally, EAM-2201 is a hybrid of two known cannabinoid compounds JWH-210 and AM-2201, both of which had previously been used as active ingredients in synthetic cannabis blends before being banned in many countries.

Pharmacology[edit]

EAM-2201 acts as a full agonist with a binding affinity of 0.380nM at CB1 and 0.371nM at CB2 cannabinoid receptors.[3]

Legal status[edit]

EAM-2201 was banned in New Zealand as a temporary class drug from 6 December 2012, after reports of addiction and psychosis associated with use of products containing EAM-2201 as an active ingredient, however this has been protested by some users who claim to have found medical benefits in the treatment of conditions such as phantom limb pain, since medicinal marijuana is not available in New Zealand and synthetic cannabis products are used as a legal alternative.[4][5]

EAM-2201 is an Anlage II controlled drug in Germany.

As of October 2015 EAM-2201 is a controlled substance in China.[6]

Detection[edit]

A forensic standard of EAM-2201 is available and commonly used in mass spectrometry.[7]

See also[edit]

References[edit]

  1. ^ Ju Hyun Kim; Hee Seung Kim; Tae Yeon Kong; Joo Young Lee; Jin Young Kim; Moon Kyo In; Hye Suk Lee (February 2016). "In vitro metabolism of a novel synthetic cannabinoid, EAM-2201, in human liver microsomes and human recombinant cytochrome P450s". Journal of Pharmaceutical and Biomedical Analysis. 119 (5): 50–58. PMID 26641707. doi:10.1016/j.jpba.2015.11.023. 
  2. ^ Nahoko Uchiyama; Maiko Kawamura; Ruri Kikura-Hanajiri; Yukihiro Goda (April 2013). "URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products.". Forensic Science International. 227 (1–3): 21–32. PMID 23063179. doi:10.1016/j.forsciint.2012.08.047. 
  3. ^ Hess, Cornelius; Schoeder, ClaraT.; Pillaiyar, Thanigaimalai; Madea, Burkhard; Müller, ChristaE. (1 July 2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. ISSN 1860-8965. PMC 4929166Freely accessible. PMID 27429655. doi:10.1007/s11419-016-0320-2. 
  4. ^ Hamish McNeilly (1 October 2012). "I was possessed by a demon, says ex-legal high user". New Zealand Herald. 
  5. ^ Bay of Plenty Times (28 November 2012). "Amputee: K2 'takes away my pain'". New Zealand Herald. 
  6. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015. 
  7. ^ "EAM-2201". Cayman Chemical. Retrieved 21 July 2015.